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Marfan syndrome is a common autosomal dominant hereditary connective tissue disorder. There is no cure for Marfan
syndrome currently. Next-generation sequencing (NGS) technology is efficient to identify genetic lesions at the exome
level. Here we carried out exome sequencing of two Marfan syndrome patients. Further Sanger sequencing validation
in other five members from the same family was also implemented to confirm new variants which may contribute to
the pathogenesis of the disease. Two new variants, including one nonsense SNP in the Marfan syndrome gene FBN1
and one missense mutation in exon 15 of LRP1, which may be related to the phenotype of the patients were identified.
The exome sequencing analysis provides us a new insight into the molecular events governing pathogenesis of Marfan
syndrome.
Virtual slide: http://www.diagnosticpathology.diagnomx.eu/vs/1229110069114125.
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Marfan syndrome is a common autosomal dominant her-
editary connective tissue disorder with prominent manifes-
tations in different organ systems, including cardiovascular,
ocular, and skeletal system [1]. Globally, about 1 in 5000 to
1 in 10,000 live newborns is affected without any racial,
geographical or occupational predilection [1-3]. The Mar-
fan syndrome gene, FBN1, was localized on chromosome
15q21 and cloned in 1991 [4]. Numerous therapy strategies
have been proposed ever since. However, the mortality re-
mains high and there is no cure for Marfan syndrome cur-
rently. This is mainly because the understanding of the
underlying mechanism is still limited. Identify new genetic
lesions of the disease may result in ideas which present al-
ternatives of up to now inadequate therapy strategies.
Next-generation sequencing (NGS) technologies is effi-
cient to identify genetic lesions at the exome level [5], espe-
cially for families that are not big enough for classical
linkage studies. Studies on familial thoracic aortic disease
[6] or other syndromes [7,8] which presents malformations* Correspondence: sdyzh56@163.com
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stated.overlapped with Marfan syndrome have identified new mu-
tations which is likely responsible for the clinical pheno-
type. However, there is no exome-sequencing study specific
for Marfan syndrome currently.
Here we carried out exome sequencing of two Marfan
syndrome patients. Further Sanger sequencing validation
in other five members from the same family was also
implemented to confirm new variants which may con-
tribute to the pathogenesis of the disease. Our investiga-
tion here may provide new insights for the molecular
mechanism of Marfan syndrome.Materials and methods
Sample and DNA preparation
The Institutional Review Board (IRB) at the Qianfoshan
hospital approved the study. Prior to their participation,
written informed documents were reviewed and ob-
tained from all subjects. Pedigree of the family is shown
in Figure 1. Peripheral blood was collected and genomic
DNA was isolated from current available cases (3:1, 4:1,
and 3:5) and several unaffected samples (3:2, 3:4, 3:6,
and 3:7). The patients were diagnosed as Marfan syn-
drome according to the revised Ghent nosology [9]
based on their reported family history and clinical fea-
tures. Detail clinical information of all patients is listedhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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Figure 1 Pedigree of Marfan syndrome family. Circles represent female participants and squares male participants. A slash through the
symbol indicates that the family member is deceased. Black symbols indicate patients with Marfan syndrome. Small circles on the top right
indicate members for whom whole-exome sequencing and Sanger sequencing validation were carried out. Arrows on the top right indicate
members for whom the PCR and Sanger sequencing validation were carried out.
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tions, systemic evaluations including skeletal features,
physical examinations, measurement of the aortic root
diameter and skin extensibility. All patients were hospital-
ized due to aortic aneurysm surgery. To identify variants
underlying the disease in this family, affected individuals
3:5 and 4:1 were selected for exome-sequencing.
Exome sequencing
Exome sequencing was performed by using the SureSelect
Human All Exon 50 Mb Kit (Agilent, Santa Clara). Gen-
omic DNA was randomly fragmented into an average size
of 500 bp by sonication. A pair of adaptors was ligated to
both ends of the DNA fragments. The adaptor-ligated
DNA products were then hybridized to the exome capture
array to capture fragments in target regions. Afterwards,
the captured fragments were amplified, purified and sub-
jected to paired-end sequencing on the Illumina Hiseq
2000 platform (Illumina, CA, USA). The sequencing step
was performed by WuXi AppTec Co.
Read mapping and variants calling
By using Fastx-tools (http://hannonlab.cshl.edu/fas-
tx_toolkit/index.html), low quality reads were discarded
(fractions of N bases over 10% or over half bases with
quality score less than 5). BWA (version 0.5.9) [10] was
used to map paired-end reads to the human reference
assembly (hg19), which was obtained from the UCSC
(University of California, Santa Cruz) database (http://
genome.ucsc.edu). PCR duplications were removed byusing SAMtools software package (version 0.1.16) [11].
Reads that aligned to the target and adjacent regions of
the two samples were collected and integrated into an
“mpileup” file with SAMtools [11] for subsequent analysis.
Variants including single nucleotide polymorphisms
(SNPs), insertions and deletions (indels) were then identi-
fied by using VarScan2 (version 2.2.8) [12] and filtered
with default parameters. Briefly, the following criteria were
used: read with non-reference calls with a frequency of
over 20% after removing reads with mapping quality < 30
and base calls with base quality < 15; if three or more vari-
ants were found within any 10 bp windows, we discarded
all variants. The identified SNVs and indels were anno-
tated with the ANNOVAR software (http://www.open-
bioinformatics.org/annovar/).
Selection of potential causative variants
We focused on the variants which have not been re-
ported in the dbSNP137 or NHLBI GO Exome Sequen-
cing Project (ESP, https://esp.gs.washington.edu/drupal/)
database before. The status of the variants in Asian popu-
lation was further checked with the 1000 Genome data
(http://www.1000genomes.org/). Variants which have been
reported in dbSNP137 or EPS and in Asian populations of
the 1000 genome were filtered. Variants shared by the two
cases were considered to be potentially related to the dis-
ease. Since Marfan syndrome is an autosomal dominant
hereditary disorder [13] and only one parent of our cases
are affected cases, the causative variants here should be
heterozygous. The impact of the shared heterozygous
Table 1 Clinical features of the patients
Individuals 3:1 3:5 4:1
Sex/age (yrs) F/53 M/47 F/24
Age at surgery (years) 46 42 22
Reason for surgery TAAA, TAD TAAA, TAD AAA
Facial features
Dolichocephaly (+) (+) (+)
Enophthalmos (+) (+) (+)
Retrognathia (+) (+) (+)
Cardiovascular system
Aortic root dimension (mm) 50 45 38
Mitral valve prolapse (−) (−) (−)
Ocular system
Lens dislocation (−) (−) (−)
Myopia (+) (−) (+)
Strabismus (−) (−) (−)
Glaucoma (−) (−) (−)
Skeletal system
Height (cm) 176 185 178
Arm span to height ratio 1.02 1.03 1.07
Pectys deformities (−) (−) (−)
Wrist and thumb sign (+) (+) (+)
Scoliosis (−) (−) (−)
Joint hypermobility (+) (+) (+)
Flat feet (+) (+) (+)
Protrusio acetabuli (+) (+) (+)
Other manifestations
Hyperextensible skin (+) (+) (+)
Skin striae (+) (−) (+)
TAAA: thoracoabdominal aortic aneurysm; TAD: thoracic aortic dissection; AAA:
abdominal aortic aneurysm.
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prediction analysis using PROVEAN [14], SIFT [15],
Polyphen-2 [16], FATHMM [17], MutationAssessor [18]
and MutationTaster [19]. Protein-altering SNVs which are
predicted to be damaging by at least three methods were
considered as candidate causative variants. Further man-
ual literature review was carried out to select variants in-
volved in the pathogenesis of Marfan syndrome. The
filtering process is illustrated in Figure 2.
Validation of selected variants
Selected variants were further validated in the two sequen-
cing samples and another patient 3:1 (Figure 1) by PCR
and Sanger sequencing. To further confirm their associ-
ation with the disease, the variants were also typed in 4
other unaffected samples in the family (Figure 1). Primers
were designed by using the Primer Premier 5 software
(PREMIER Biosoft International, Palo Alto, Calif.). PCRamplification in 50 μl reaction was performed as follows:
95°C for 2 min, 35 cycles of 95°C for 15 sec, 60°C for
20 sec, 72°C for 30 sec, and 72°C for 2 min. The PCR
products purification was completed with the E.Z.N.A.®
Gel Extraction Kit. Sanger sequencing was performed in
both forward and reverse direction on an ABI 3730 DNA
Analyzer. Sequence trace files were analyzed manually.
Results
We analyzed a four-generation Marfan syndrome family
including 10 affected members. We sequenced the exome
of two patients (Figure 1, 4:1 and 3:5). After target enrich-
ment, whole exome DNA libraries from the two relatives
were sequenced in 100 bp paired-end reads. A total of
21.86 Gb data were obtained and 10.72 Gb data were
uniquely mapped the target region, achieving a mean
depth of 97.2 × and 111.6 ×, respectively (Table 2). The
coverage of target region for each sample was all over
99%. The capture rate for 4:1 and 3:5 was 70.40% and
65.94% respectively.
Only uniquely mapped sequences (target and adjacent
regions) were used for variants detection. Reads of the
two samples were firstly integrated into an “mpileup” file
with SAMtools [11]. Variants including SNPs and indels
were then detected by using VarScan2 [12]. For the two
affected samples, only one of their parents is Marfan
syndrome patients (Figure 1). Thus, the causative vari-
ants here should be heterozygous. We focused on the
heterozygous they shared in common for further ana-
lysis. In total, 2239 heterozygous protein-altering vari-
ants, including 2117 SNPs and 122 indels were detected
in the two patients. After the filtering process, 212 vari-
ants, including 32 indels, 170 missense SNPs, and 10
nonsense SNPs were remained.
Based on literature review and the function prediction re-
sults (Figure 2), we selected 7 variants in 7 genes (Table 3)
which may involve in the pathogenesis for further PCR and
Sanger sequencing validation. All of the 7 variants were val-
idated in the original two exome sequencing samples and
another patient (3:1). As shown in Table 4, three variants
were only detected in Marfan syndrome patients, including
one nonframeshift deletion in DSC2, one missense SNPs in
LRP1, and one stopgain SNP in FBN1. According to the
Kyoto Encyclopedia of Genes and Genomes (KEGG) path-
way annotation, DSC2 is involved in the Arrhythmogenic
right ventricular cardiomyopathy pathway (hsa05412). The
LRP1 protein is involved in the RNA degradation process
(hsa03018) and two diseases: Malaria (hsa05144) and Alz-
heimer's disease (hsa05010).
Discussion
We performed exome sequencing for two patients from
a four-generation Marfan syndrome family to identify
key genetic lesions contributing to the disease. Further
2239 heterozygous protein-altering variants
(2117 nonsynonymous SNPs and 122 indels)
Reported in dbSNP137
or ESP and Asian population 
of the 1000 Genome?
No
170 missense SNPs 10 nonsense SNPs and 32 indels
Predicted to be









Figure 2 The filtering process of the selected variants for validation. EPS: NHLBI GO Exome Sequencing Project.
Table 2 Data summary of exome sequencing
Samples 4:1 3:5
Raw data (Gb) 8.45 13.41
Clean data (Gb) 8.40 13.40
Uniquely mapped on the genome (Gb) 7.09 8.69
Mapped on target region (Gb) 4.99 5.73
Capture rate (%) 70.40 65.94
Mean depth of target region (×) 97.20 111.60
Coverage of target region
1 × 99.50% 99.50%
10 × 92.79% 93.51%
20 × 80.86% 82.44%
Note: The id of each sample is in correspondence with that in Figure 1.
×: times or fold. For a specific position, 10 × means 10 sequenced reads
provide valid information for the nucleotide at this position.
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sequencing patients, one another patient and 4 unaffected
samples from the family was carried out for validation.
Three new variants, including 1 deletion in DSC2, 1 mis-
sense SNPs in LRP1, and 1 nonsense SNP in FBN1 were
confirmed to exist only in Marfan syndrome patients.
We reported a new nonsense mutation in exon 8 of
FBN1 which is shared in three patients of the family
(Figure 3). Defect of FBN1 has been considered to be
the cause of Marfan syndrome since 1991 [20]. Protein
encoded by FBN1 is connective protein fibrillin-1 [21], a
matrix glyco protein widely distributed in elastic and
nonelastic tissues. Incorporation of abnormal fibrillin
proteins into microfibrils would result in structurally in-
ferior connective tissues. Fibrillin-1 could bind to the la-
tent form of TGFβ and inhibit TGFβ from exerting its
Table 3 Detail information of the selected variants
ID Chr Start End Typea Gene Ref depthb Alt depthb Function prediction
4:1 3:5 4:1 3:5 PROVEAN SIFT Polyphen-2 FATHMM MutationTaster MutationAssessor
1 3 53531321 53531321 C/G CACNA1D 66 89 91 81 −1.894 0.03 Benign −3.74 Disease causing 0.345
2 6 7727522 7727522 -/AGC BMP6 14 8 7 22 −0.67 - - - - -
3 12 57556718 57556718 G/A LRP1 79 70 69 69 −1.693 0.041 Probably damaging −4.26 Disease causing 1.225
4 12 974355 974355 -/C WNK1 75 106 105 78 - - - - - -
5 15 48826326 48826326 G/T FBN1 28 41 26 25 - - - - - -
6 15 100252710 100252715 CAGCAG/- MEF2A 65 57 38 85 1.329 - - - - -
7 18 28648998 28649000 TCC/- DSC2 79 91 61 43 −6.656 - - - - -
aThe first allele is the reference allele.
bDepth of the alleles. The id of each sample is in correspondence with that in Figure 1.
PROVEAN: If the PROVEAN score is < = −2.5, the protein variant is predicted to be deleterious. If the score is above the −2.5, the variant is predicted to be neutral.
SIFT: Ranges from 0 to 1. The amino acid substitution is predicted damaging if the score is < = 0.05, and tolerated if the score is > 0.05.
MutationAssessor: Range from −5.76 to 5.73. The variant is predicted non-functional if the score is < =1.938, and functional if the score is > 1.938.














Table 4 Validation results of the seven selected variants
ID Ref Alt Gene Samples
4:1 3:5 3:1 3:2 3:4 3:6 3:7
1 C G CACNA1D √ √ √ × × × √
2 - AGC BMP6 √ √ √ √ √ × √
3 G A LRP1 √ √ √ × × × ×
4 - C WNK1 √ √ √ × √ √ ×
5 G T FBN1 √ √ √ × × × ×
6 CAGCAG - MEF2A √ √ √ √ √ √ √
7 TCC - DSC2 √ √ √ × × × ×
Note: The ID of each variant is in correspondence with that in Table 3. The id
of each sample is in correspondence with that in Figure 1. “√” denotes same
results as exome sequencing analysis and “×” means no variant was detected.









Figure 3 Sanger sequencing results for the three new identified varia
The two arrows indicate positions of the nonsense SNP in FBN1 and the m
the identified deletion is shown in the red frame.
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result in increased level of TGFβ, which is deleterious
for vascular smooth muscle development and the integ-
rity of the extracellular matrix. Schrijver et al. [22] de-
scribed that nonsense mutations of FBN1 appeared to be
associated with more severe skeletal findings. Marfan
patients with nonsense mutations of FBN1 were also
reported to be with a significantly lower incidence of
ectopia lentis [23]. In consistent with these findings, our
patients showed severe skeletal abnormality and no sign
of lens dislocation. In addition, aortic dissections were
reported to be common in patients with nonsense muta-
tions of FBN1 [22]. Two of our patients were suffered
from aortic dissections. Moreover, we didn’t detect any
other protein-altering mutations in this gene. Further in-
vestigation on this point mutation is warranted.
We also confirmed a missense mutation in exon 15 of
LRP1 (Figure 3). Protein encoded by this gene is an endo-
cytic receptor, which is a receptor for TGFβ1 and is re-
quired for TGFβ mediated inhibition of cell proliferation.A DSC2:TCC>-
nts. The id of each sample is in correspondence with that in Figure 1.
issense SNP in LRP1. For DSC2, the reverse chain was sequenced, and
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LRP1 and the reduction in LRP1 protein expression may be
associated with aneurysm progression [24,25]. Since all our
patients are suffered from aortic aneurysm and the new
missense mutation of LRP1 is the only protein-altering vari-
ant we detected in this gene, it is possible that this dam-
aging mutation results in dysfunction of the protein,
contributing to the pathogenesis of aortic aneurysm. There-
fore, the missense mutation we identified here may serve as
a potential target for future research on Marfan patients
with aortic aneurysm.
We also detected a deletion in DSC2 which is shared
in all patients (Figure 3). The relationship of this gene
and Marfan syndrome has not been reported before. Ac-
cording to the KEGG pathway annotation, the protein
encoded by this gene is involved in the Arrhythmogenic
right ventricular cardiomyopathy (ARVC) pathway
(hsa05412). Cardiovascular malformation is one of the
prominent manifestations of Marfan syndrome. How-
ever, none of our patients were suffered from ARVC.
Further investigation is needed to confirm the contribu-
tion of this mutation to Marfan syndrome.
Conclusion
In summary, exome sequencing of two Marfan syndrome
patients and further Sanger sequencing validation in other
members from the same family were carried out to identify
new variants which may contribute to the pathogenesis of
the disease. Two new variants, including one nonsense
SNP in the Marfan syndrome gene FBN1 and one missense
mutation in exon 15 of LRP1, which may be related to the
phenotype of the patients were identified. Thus, the exome
sequencing analysis provides us a new insight into the mo-
lecular events governing the molecular mechanism of Mar-
fan syndrome. The variants we identified here may provide
new targets for further therapeutic investigations.
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